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Objectives To assess in pregnant women with HIV the rates of
amniocentesis and chorionic villus sampling (CVS), and the
outcomes associated with such procedures.
Design Observational study. Data from the Italian National
Program on Surveillance on Antiretroviral Treatment in
Pregnancy were used.
Setting University and hospital clinics.
Population Pregnant women with HIV.
Methods Temporal trends were analysed by analysis of variance
and by the Chi-square test for trend. Quantitative variables were
compared by Student’s t-test and categorical data by the Chi-
square test, with odds ratios and 95% confidence intervals
calculated.
Main outcome measures Rate of invasive testing, intrauterine
death, HIV transmission.
Results Between 2001 and 2015, among 2065 pregnancies in
women with HIV, 113 (5.5%) had invasive tests performed. The
procedures were conducted under antiretroviral treatment in 99
cases (87.6%), with a significant increase over time in the
proportion of tests performed under highly active antiretroviral
therapy (HAART) (100% in 2011–2015). Three intrauterine
deaths were observed (2.6%), and 14 pregnancies were terminated
because of fetal anomalies. Among 96 live newborns, eight had no
information available on HIV status. Among the remaining 88
cases with either amniocentesis (n = 75), CVS (n = 12), or both
(n = 1), two HIV transmissions occurred (2.3%). No HIV
transmission occurred among the women who were on HAART at
the time of invasive testing, and none after 2005.
Conclusions The findings reinforce the assumption that invasive
prenatal testing does not increase the risk of HIV vertical
transmission among pregnant women under suppressive
antiretroviral treatment.
Keywords Amniocentesis, birth defects, chorionic villus sampling,
HIV, invasive testing, mother-to child HIV transmission,
pregnancy, prenatal diagnosis.
Tweetable abstract No HIV transmission occurred among women
who underwent amniocentesis or CVS under effective anti-HIV
regimens.
Linked article This article is commented on by C Eppes, p. 1224
in this issue. To view this mini commentary visit http://
dx.doi.org/10.1111/1471-0528.14194.
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Introduction
The widespread application of effective preventive measures
that minimise the risk of HIV transmission from HIV-
infected mothers to their children, has levelled rates of
transmission at 0.5–2.0%1,2 and increased pregnancy rates
and family planning among people with HIV.3 Within this
context, prenatal diagnosis of congenital abnormalities and
chromosomal anomalies represents an issue of growing rel-
evance. In the early decades of HIV epidemic, invasive
diagnostic procedures that facilitate fetal exposure to
maternal blood, such as amniocentesis and chorionic villus
sampling, were usually discouraged, assuming an increased
risk of vertical transmission associated with such proce-
dures.4,5 In more recent studies, conducted against a back-
ground of maternal antiretroviral treatment, rates of
transmission were lower, and currently available evidence
suggests minimal or no additional risk of transmission if
the procedure is performed under treatment with effective
combination regimens (highly active antiretroviral therapy,
HAART). Most of the published studies are, however,
based on a limited number of cases, and there is a need to
further explore the impact of invasive procedures on both
HIV transmission and pregnancy outcomes.6–10
To provide further information on this issue, we anal-
ysed data from a large national cohort of pregnant women
with HIV, examining rates of invasive testing and outcomes
associated with the procedures.
Methods
Data from the National Program on Surveillance on
Antiretroviral Treatment in Pregnancy, which represents
the main cohort of HIV-infected pregnant women in Italy,
were used.11 This is a national observational study of preg-
nant women with HIV established in Italy in 2001 that
covers, based on available prevalence data,12 roughly
30–40% of live births from women with HIV in Italy. Only
HIV-positive pregnant women are included, and no specific
guidance is given in terms of treatment of HIV infection or
prophylaxis for mother-to-child transmission, which are
decided by the treating physician. Ethics approval was
obtained on 28 September 2001 from the Ethics Committee
of the I.N.M.I. Lazzaro Spallanzani in Rome (ref. delibera-
tion no. 578). Major birth defects were defined according
to the Antiretroviral Pregnancy Registry definition13 and
grouped as chromosomal anomalies or major structural
defects. Antiretroviral treatment was classified, according to
the number of drugs in the regimen, as monotherapy, dual
therapy or HAART (three or more drugs, excluding low-
dose ritonavir).
Invasive antenatal tests were defined as amniocentesis
and chorionic villus sampling (CVS); no specific study
protocol was issued for these procedures, given the pres-
ence of reference national guidelines for the general popu-
lation14 and specific recommendations for women with
HIV.15 Non-invasive screening tests for chromosomal
anomalies were defined by the following: ultrasonographic
assessment of nuchal translucency (usually conducted
between 10 and 13 completed weeks of pregnancy); first
trimester serum levels of pregnancy-associated plasma pro-
tein A (PAPP-A) and free b-hCG (between 10 and
13 weeks); second-trimester serum levels of alpha-fetopro-
tein (AFP), b-hCG and unconjugated oestriol (uE3) (be-
tween 14 and 20 weeks). The standard risk cut-off defining
positivity of non-invasive tests was 1/250.14
The study collected data since December 2001. For the
current analysis, the study period (2001–2015) was divided
in three intervals of 5 years each (2001–2005, 2006–2010,
2011–2015). Temporal trends were analysed by one-way
analysis of variance and by the Chi-square test for trend.
Quantitative variables were compared by Student’s t-test
and categorical data by the Chi-square test, with odds
ratios (OR) and 95% confidence intervals (CI) calculated.
P-values <0.05 were considered significant. All statistical
analyses were performed with the SPSS software, version 22
(IBM Corp., Released 2013, Armonk, NY, USA).
Results
As of 17 April 2015, following exclusion of pregnancies
ending in miscarriage or termination in the first 8 weeks of
pregnancy, 2065 pregnancies had available information on
pregnancy outcome (77 miscarriages before 22 weeks, 91
voluntary pregnancy terminations, 24 stillbirths at or after
22 weeks, and 1873 pregnancies ending in one or more live
births).
Among these pregnancies, 113 (5.5%) had invasive tests
(CVS or amniocentesis) performed in 18 different clinical
centres. Two women with pregnancy at risk had two
sequential invasive tests in the same pregnancy (two
amniocenteses in the first case and a CVS followed by
amniocentesis in the other), for a total of 115 tests per-
formed (amniocentesis 97, CVS 18).
The mean age of the study population remained substan-
tially unchanged during the entire period of observation;
conversely, the rate of non-invasive tests for chromosomal
anomalies increased significantly in more recent years
(P < 0.001, Table 1). The rate of invasive testing in preg-
nancy (overall 5.5%) remained stable during the study per-
iod, but the proportion of women who were on HAART at
the time of amniocentesis or CVS increased significantly,
reaching 100% in 2011–2015 (P = 0.001, Table 1).
Having a first antenatal visit in the first 18 weeks of
pregnancy increased significantly the likelihood of both
non-invasive screening tests (OR 4.411, 95% CI 3.088–
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6.302, P < 0.001), and invasive diagnostic procedures in
pregnancy (OR 2.961, 95% CI 1.363–6.430, P = 0.006). In
25 cases, invasive tests followed a positive non-invasive
screening test (biochemical markers 15; nuchal translucency
10). The invasive test confirmed chromosomal anomalies
in 2/15 (13.3%) of biochemical-positive (PAPP-A and free
b-HCG) cases (both trisomy 21), and in 3/10 (30%) of
nuchal translucency-positive cases (trisomy 21: 2, trisomy
18: 1).
Among 113 pregnancies with invasive testing, three
intrauterine deaths were observed (2.6%), all in women
who had second trimester amniocentesis performed: in two
of them, which occurred in the third trimester (week 26
and 36, respectively), maternal or fetal conditions poten-
tially implicated in the death were present (HELLP syn-
drome, and trisomy 21 associated with structural defects,
respectively). In the third case, intrauterine death occurred
at week 19 because of severe chorioamnionitis without any
maternal disease or fetal defect. The woman had started an
HAART-based regimen (zidovudine, lamivudine, lopinavir/
ritonavir) at week 13.
In 14 pregnancies, invasive testing was followed by elec-
tive termination of pregnancy for fetal anomaly (ETOPFA).
In 11 of these cases the invasive test had shown chromoso-
mal anomalies (Trisomy 18: 5; Trisomy 21: 4) or homozy-
gotic haemoglobin disorders (sickle-cell disease: 1;
thalassaemia: 1). In the other three cases the results of
invasive testing for chromosomal anomalies was either neg-
ative (2) or unknown (1), but ultrasonography had shown
major structural defects (hydrocephalus: 1, cystic hygroma:
1, bilateral arm hypodysplasia: 1).
Ninety-six pregnancies ended with singleton live births:
among the infants, seven (7.3%, 95% CI 2.1–12.5) had
major birth defects: one chromosomal anomaly detected
antenatally by amniocentesis/karyotype (Trisomy X), and
six structural defects, four detected antenatally by ultra-
sonography: bilateral club foot (2), labiopalatoschisis (1),
septal cardiac defect (1), and two detected at birth: poly-
dactyly (1) and atrial septal defect with pulmonary
hypertension (1). Overall, among 113 cases with any preg-
nancy outcome, invasive testing allowed 11 chromosomal
anomalies to be detected (9.7%).
Among 95 live births with information on mode of
delivery, only one was delivered vaginally (1.1%). For 25
pregnancies in the cohort, HIV transmission could not be
evaluated either because of termination of pregnancy/in-
trauterine death (n = 17) or because of infant loss to fol-
low up/unavailability of virological data (n = 8). Among
88 women with invasive test performed and live births with
known HIV status, two cases of HIV transmission were
observed (2.3%, 95% CI 0–5.4%). Neither of these women
were on HAART at the time of invasive testing, whereas all
the remaining 86 non-transmitting women were (amnio-
centesis 78, CVS 8). The two cases of transmission
occurred in 2003 and 2005, respectively, and no cases were
observed after 2005. In the first case, the mother, an
heterozygotic carrier of beta-thalassaemia, was HIV-nega-
tive at entry in pregnancy, had CVS at first trimester, and
seroconverted for HIV during pregnancy, with HIV infec-
tion diagnosed at third trimester and antiretroviral treat-
ment (lamivudine plus zidovudine) started at week 34,
with no available information on HIV viral load in preg-
nancy or at delivery. In the second case, the mother was
41 years old at conception, started zidovudine monother-
apy at week 14, had amniocentesis at second trimester
under antiretroviral treatment, with viral load levels of
2300 and 5300 copies/ml at second and third trimester,
respectively. Both cases had elective caesarean delivery,
intrapartum administration of intravenous zidovudine, and
postnatal infant prophylaxis with zidovudine for 6 weeks.
Discussion
Main findings
We assessed, in a large national series of pregnant women
with HIV, the rate of invasive testing in pregnancy and the
outcomes associated with such procedures. Rate of
intrauterine death was low and no cases of HIV
Table 1. Temporal trends in age, testing, treatment status at invasive testing and HIV transmission (2001–2015)
All (2001–2015) 2001–2005 2006–2010 2011–2015 P-value
Age (years, mean) (n = 2052) 32.2 31.9 32.5 32.1 0.107*
Invasive tests in pregnancy, % (n = 2065) 5.5 (113/2065) 5.2 (51/975) 6.1 (53/872) 4.1 (9/218) 0.933**
Non-invasive tests in pregnancy, % (n = 2065) 47.9 (799/1667) 41.2 (327/794) 54.1 (379/701) 54.1 (93/172) <0.001**
Invasive tests on ARV, % (n = 113) 87.6 (99/113) 78.4 (40/51) 94.3 (50/53) 100.0 (9/9) 0.009**
Invasive tests on HAART, % (n = 112) 76.8 (86/112) 62.7 (32/51) 86.5 (45/52) 100.0 (9/9) 0.001**
HIV transmission, % (n = 88) 2.3 (2/88) 5.4 (2/37) 0 (0/44) 0 (0/7) 0.130**
*ANOVA.
**Chi-square for trend.
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transmission occurred when invasive tests were performed
under HAART coverage.
Strengths and limitations
We were unable to evaluate formally whether amniocentesis
or CVS increases the risk of HIV transmission. This limita-
tion originates from sample size issues and minimal event
rate in the presence of universal treatment administration
in pregnancy. The case series evaluated, despite being one
of the largest reported in women with HIV, remains there-
fore susceptible to type 2 (false negative) error, particularly
for CVS, (with only 13 cases evaluated). The absence of
transmission among women on HAART is nonetheless
reassuring. The strengths of the present study include the
relatively large numbers, the multicentre observation, the
definition of temporal trends, and the description of cases
with non-invasive tests followed by karyotype assessment.
Importantly, our survey included not only amniocentesis
but also a number of cases of CVS that were not described
in previously published reports.
Interpretation
The observed rate of invasive testing was roughly 5%, consis-
tent with data from the large national study by Mandelbrot
et al.9 from France (4.7% in 2005–2006). Other studies had
shown slightly different rates: in a study conducted in Italy
between 1997 and 2003,6 the rate of invasive testing was
8.1%, whereas in the sample followed by Simoes et al.10 in
Portugal between 1996 and 2011, rate of amniocentesis was
3.4%. Such local differences may be due to demographics of
the population followed, maternal attitude toward testing, or
case selection favouring a more frequent undertaking of
invasive procedures in reference centres. Overall, the rate of
invasive testing appears to be lower in women with HIV than
in the general population in Italy: national data for 2013
showed rates of 10.6% for amniocentesis and of 4.2% for
CVS, with large regional variations.16 Although the rate of
invasive testing among women with HIV remained substan-
tially unchanged between 2001 and 2015, the rate of non-
invasive tests showed a significant increase during the same
period that was not attributable to temporal changes in
maternal age. These findings indicate a more targeted use of
invasive testing based on the results of non-invasive tests,
and an improved inclusion in the pathway of prenatal diag-
nosis in recent years.
Among the women who had biochemical screening tests
followed by invasive testing, only 13% of positive screening
biochemical tests were subsequently confirmed to be chro-
mosomal anomalies at invasive testing. This finding should
be further explored, considering the existing discussion
about a possible higher risk of positive screening tests
among women with HIV due to differences in levels of
alpha-fetoprotein, human chorionic gonadotropin and
unconjugated oestriol.17–19 Available information on this
issue is very limited, as there is a scarcity of data on
sequential non-invasive and invasive testing in pregnant
women with HIV: in the study by Coll et al.7 among 10
cases with indication to amniocentesis (7/10 with a positive
biochemical screening test), two (20%) had chromosomal
anomalies. Further studies, possibly based on pooling of
different national cohorts of pregnant women with HIV,
should specifically address this issue to avoid a potential
excess of invasive testing due to increased likelihood of
positive biochemical screening tests.
A confirmed prenatal diagnosis of chromosomal anoma-
lies was frequently followed by elective termination of preg-
nancy. This finding is not unexpected, and consistent with
the higher proportion of termination following invasive
tests compared with noninvasive tests9 and following a
diagnosis of chromosomal anomalies compared with struc-
tural defects.20
A known adverse consequence of invasive procedures is
fetal death. In our study, three cases of intrauterine deaths
were observed (2.6%). One of these cases was considered pos-
sibly to be related to the procedure because invasive testing
was complicated by development of chorioamnionitis in the
absence of other predisposing conditions, whereas the other
two were considered unrelated because of congenital defects
and HELLP syndrome, respectively. Variable rates have been
reported for intrauterine death in women with HIV undergo-
ing invasive procedures: Mandelbrot et al.9 observed a low
rate (0.6%), with no substantial difference in the proportion
of perinatal death between cases with and without invasive
testing (0.9% versus 1.2%), whereas in the study by Somigli-
ana et al.6 the rate of intrauterine death was higher (5%),
with one case considered to be related to the invasive proce-
dure. Such findings are difficult to interpret, given the limited
information and the variable rates of intrauterine death
reported in the general population of women with HIV. Early
studies, conducted in a context of high maternal viral load/
low CD4 cell count and no use of HAART, had shown high
rates (11%),21 but more recent studies have shown much
lower rates (1.9%).22 Advanced maternal disease or high
plasma viral load may represent significant predictors of this
outcome and explain the above differences.23,24
In terms of HIV transmission, the rate observed was 2.3%,
with no cases observed after 2005 and no transmission events
among women on HAART. Overall, these findings are con-
sistent with data from two other European studies that also
showed no transmission among the women who were on
HAART at the time of the procedure9,10 and with the less
recent Italian study, where the two cases of transmission that
followed invasive testing (3.3%) involved one woman not on
treatment and one woman on zidovudine monotherapy.6
HIV transmission may occur independently of the invasive
diagnostic test conducted, and other factors might play a
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role. A timely diagnosis of HIV in pregnancy is essential to
avoid invasive testing being performed in women with
unsuppressed viral replication because of undiagnosed HIV
infection. Even in the presence of a negative HIV test at entry
in pregnancy, particular attention should be paid to identify-
ing HIV seroconversion in pregnancy, because of the higher
risk of transmission associated with this occurrence. One of
the two cases in our study involved primary infection, as well
as the only observed case among the women with amniocen-
tesis followed by Simoes et al.10 between 1996 and 2011.
Finally, we observed a minimal rate of vaginal delivery
among women with amniocentesis or CVS. This finding is
partly due to an overall low rate in the cohort (overall,
roughly 4–5% between 2001 and 2016), compared with other
European countries,25 but it could also be due to preferred
elective caesarean delivery, for unclear reasons, among
women who underwent invasive testing.
Conclusion
Our data reinforce the assumption that invasive prenatal
testing does not increase the risk of vertical transmission in
HIV-infected pregnant women under suppressive antiretro-
viral treatment. Invasive procedures, however, also carry
some risk of other adverse pregnancy outcomes, particu-
larly fetal death, which should always be considered. In the
future, following further evaluation and validation in the
general population, prenatal diagnosis in women with HIV
could also include non-invasive tests based on evaluation
of fetal cell-free DNA in maternal blood, which have shown
promising results in preliminary studies.26
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